TACE With Thermosensitive Nanogel Versus Embosphere for HCC
To verify the safety and efficacy of TACE withThermosensitive Nanogel Embolic Agent for HCC.
| Condition(s) | Unresectable Hepatocellular Carcinoma |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | To verify the safety and efficacy of TACE withThermosensitive Nanogel Embolic Agent for HCC. |
| Who can participate | Inclusion Criteria: 1. Chinese Liver Cancer Staging Scheme, stage IIb-Illa, as well as those with stage Ia-Ila HCC, unsuitable or unwilling to undergo surgical resection, transplantation, or ablation; 2. Liver function status: Child-Pugh A or B 3. Eastern Cooperative Oncology Group score: 0-2 points; 4. With at least one measurable, unembolized liver tumor lesion (1-10 cm) ; 5. Willing to participate in this trial and sign the informed consent. Exclusion Criteria: 1. The target lesion has been embolized before or require combined with other treatment(s); 2. Diffuse or with extrahepatic metastasis; 3. Coagulation dysfunction (PT prolonged beyond the upper limit of normal for 3 seconds); 4. Severe renal dysfunctions (creatinine clearance rate \<30 ml/min); 5. Severe liver dysfunctions (alani |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Lead sponsor | Zhongda Hospital |
| Locations | Nanjing, China |
| Start date | 2024-09-10 |
| NCT ID | NCT06593964 |
| Official listing | https://clinicaltrials.gov/study/NCT06593964 |